Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)

This is a single center, single arm and open-label study to determine the safety of mRNA modified HBV-TCR redirected T-cells and to analyze the changes in tumor microenvironment caused by these HBV-TCR redirected T-cells in subjects with HBV-related HCC who are not amenable to/failed conventional treatment.

Trial Details

NCT ID
NCT04745403
Phase
PHASE1
Sponsor
Lion TCR Pte. Ltd.
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • mRNA HBV/TCR T-cells
Locations (sample)
  • Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  • Presence of primary hepatocellular carcinoma in the liver with presence of measurable tumour by RECIST 1.1 criteria, that is not amenable to, or fa…
  • Serum HBsAg positivity
  • Non-cirrhotic or compensated cirrhosis Child-Pugh A (5 - 6 points)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →